Andrew Jackson
Director of Finance/CFO presso CALIDI BIOTHERAPEUTICS, INC.
Patrimonio netto: 96 $ in data 31/03/2024
Profilo
Andrew C.
Jackson is currently the Chief Financial Officer at Calidi Biotherapeutics, Inc. He previously held the same position at Celladon Corp.
from 2014 to 2016, at AltheaDx, Inc. from 2016 to 2018, and at Ra Medical Systems, Inc. from 2018 to 2022.
From 2022 to 2023, he was the Chief Financial Officer at Eterna Therapeutics, Inc. Jackson received his undergraduate degree from the University of Minnesota in 1992 and his graduate degree from San Diego State University in 2006.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
CATHETER PRECISION, INC.
0.00% | 17/05/2023 | 197 ( 0.00% ) | 96 $ | 31/03/2024 |
ETERNA THERAPEUTICS INC.
-.--% | 26/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Andrew Jackson
Società | Posizione | Inizio |
---|---|---|
CALIDI BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 30/10/2023 |
Precedenti posizioni note di Andrew Jackson
Società | Posizione | Fine |
---|---|---|
ETERNA THERAPEUTICS INC. | Director of Finance/CFO | 04/05/2023 |
CATHETER PRECISION, INC. | Chief Executive Officer | 30/03/2020 |
ALTHEADX INC | Director of Finance/CFO | 01/04/2018 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01/03/2016 |
Formazione di Andrew Jackson
San Diego State University | Graduate Degree |
University of Minnesota | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ETERNA THERAPEUTICS INC. | Health Technology |
CALIDI BIOTHERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
AltheaDx, Inc.
AltheaDx, Inc. Pharmaceuticals: MajorHealth Technology AltheaDx, Inc. operates as a commercial stage molecular diagnostics company which specializes in pharmacogenetics. It focuses in depression and anxiety, clinical publications, and IDgenetix testing process. The company was founded by Francois Ferre and Magda Marquet and is headquartered in San Diego, CA. | Health Technology |
Ra Medical Systems, Inc.
Ra Medical Systems, Inc. Medical SpecialtiesHealth Technology Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of vascular immune-mediated inflammatory diseases. Its product, the Destruction of Arteriosclerotic Blockages by laser Radiation Ablation (DABRA) laser and single-use catheter, together referred to as DABRA, is used as a tool in the treatment of peripheral artery disease which commonly occurs in the legs. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Fort Mill, SC. | Health Technology |
- Borsa valori
- Insiders
- Andrew Jackson